LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

The Federal Circuit left in place a pair of orders blocking two competitors of Regeneron Pharmaceuticals Inc. from marketing ...

If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...